The company is showcasing new development solutions and advanced digital technologies including its new OSD Express and Steriles Express solutions for drug development.
|Articles|March 27, 2023
Illuminating the State of Outsourcing with Stephen Houldsworth (DCAT 2023)
Author(s)Grant Playter
Stephen Houldsworth, VP and Head of Platform Management & Marketing at CordenPharma, dives into ongoing trends in the outsourcing space.
Advertisement
As part of ongoing coverage of DCAT, the PharmTech editors touched base with Stephen Houldsworth, vice-president and head of Platform Management & Marketing at CordenPharma. In in our discussion, Stephen touched on various topics within the outsourcing market, including:
- Recent investments and the strategic rationale behind them.
- Ongoing industry trends and what customers are looking for.
- Bold predictions for where the industry will be five years down the line.
For more of our coverage on DCAT in 2023, viewers can visit
Advertisement
Related to this article
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Jason Bertola, executive director of Commercial Development for the Advanced Synthesis Platform at Lonza in North America, explains the demand for spray drying and the hurdles involved with scale up, in an interview with PharmTech.
Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Q&A: Patient-Centric Drug Development Should Start at Product Definition
2
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
3
PharmTech AI Pulse Check: AI Watermark Vulnerability
4
Clinical Trial Delays: FDA’s Expedited IND Pilot vs China’s 818 Decree
5